WO2023224097A1 - 膜形成用組成物、膜状組成物及びその利用 - Google Patents

膜形成用組成物、膜状組成物及びその利用 Download PDF

Info

Publication number
WO2023224097A1
WO2023224097A1 PCT/JP2023/018619 JP2023018619W WO2023224097A1 WO 2023224097 A1 WO2023224097 A1 WO 2023224097A1 JP 2023018619 W JP2023018619 W JP 2023018619W WO 2023224097 A1 WO2023224097 A1 WO 2023224097A1
Authority
WO
WIPO (PCT)
Prior art keywords
fatty acid
composition
film
sucrose
acid ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2023/018619
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
めぐみ 武田
卓也 松井
岳 高田
豊 奥田
勇 佐伯
達哉 本庄
正樹 佐藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Towa Pharmaceutical Co Ltd
Original Assignee
Towa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Towa Pharmaceutical Co Ltd filed Critical Towa Pharmaceutical Co Ltd
Priority to US18/865,316 priority Critical patent/US20250302753A1/en
Priority to JP2024521982A priority patent/JPWO2023224097A1/ja
Priority to EP23807698.8A priority patent/EP4527411A4/en
Publication of WO2023224097A1 publication Critical patent/WO2023224097A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/10—Foods or foodstuffs containing additives; Preparation or treatment thereof containing emulsifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes

Definitions

  • the present invention provides at least one surfactant selected from a nonionic surfactant selected from sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester or a higher alcohol surfactant, and a fatty acid having a high water solubility.
  • the present invention relates to a film-forming composition dispersed in a liquid containing molecules and a method for producing the same.
  • the present invention uses a water-soluble polymer as a base material, and the base material contains a nonionic surfactant selected from sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester or a higher alcohol surfactant.
  • the present invention relates to a film composition in which at least one surfactant and a fatty acid are dispersed.
  • the present invention relates to a pharmaceutical or food composition coated with a film-forming composition.
  • the present invention relates to a method for producing a pharmaceutical composition or a food composition having a coating layer made of a film-forming composition.
  • TECHNICAL FIELD The present invention relates to a method for producing a pharmaceutical composition or food composition having moisture-proof properties, which includes a step of coating the pharmaceutical composition or food composition with a film-forming composition.
  • the present invention relates to a method for coating a pharmaceutical composition or a food composition, which includes the step of coating the pharmaceutical composition or food composition with a film-forming composition.
  • the present invention relates to a method for moisture-proofing a pharmaceutical composition or a food composition, which includes a step of coating the pharmaceutical composition or food composition with a film-forming composition.
  • Non-Patent Document 1 describes a coating agent using stearic acid, hydroxypropylcellulose, and poloxamer 124.
  • Non-Patent Document 1 has room for improvement in moisture resistance. Therefore, it is an object of the present invention to provide a new means for improving moisture resistance.
  • the present inventors have proposed a method of combining at least one surfactant selected from a nonionic surfactant selected from sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester or a higher alcohol surfactant, and a water-soluble polymer.
  • the present invention was completed based on the discovery that a new material with excellent moisture resistance can be provided by combining a fatty acid with a fatty acid.
  • the present invention provides a film-forming composition in which a nonionic surfactant that is at least one of sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester and a fatty acid are dispersed in a liquid containing a water-soluble polymer. provide something.
  • the present invention uses a water-soluble polymer as a base material, and a nonionic surfactant that is at least one of sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester, and a fatty acid are dispersed in the base material.
  • a film composition is provided.
  • the present invention provides a pharmaceutical composition coated with the above film-forming composition.
  • the present invention provides a food composition coated with the above film-forming composition.
  • the present invention provides a film-forming composition comprising a step of mixing a nonionic surfactant that is at least one of sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester, a fatty acid, and a water-soluble polymer.
  • a nonionic surfactant that is at least one of sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester, a fatty acid, and a water-soluble polymer.
  • the present invention includes a step of mixing and heating a nonionic surfactant that is at least one of sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester and a fatty acid, and heating a liquid containing a water-soluble polymer.
  • a method for producing a film-forming composition which includes a step of adding and mixing a heated liquid to a heated mixture of a nonionic surfactant and a fatty acid.
  • the present invention involves mixing a nonionic surfactant that is at least one of sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester with a fatty acid, heating the mixture, heating a liquid containing a water-soluble polymer, and heating the mixture.
  • a step of manufacturing a film-forming composition by adding and mixing a heated liquid to a mixture of a nonionic surfactant and a fatty acid, and a step of applying a coating layer to a pharmaceutical composition using the film-forming composition.
  • a method for producing a pharmaceutical composition having a coating layer the method comprising the step of forming a pharmaceutical composition.
  • the present invention involves mixing a nonionic surfactant that is at least one of sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester with a fatty acid, heating the mixture, heating a liquid containing a water-soluble polymer, and heating the mixture.
  • a step of manufacturing a film-forming composition by adding and mixing a heated liquid to a mixture of a nonionic surfactant and a fatty acid, and a step of applying a coating layer to a food composition using the film-forming composition.
  • a method for producing a food composition having a coating layer the method comprising the step of forming a food composition.
  • the present invention provides a method for producing a pharmaceutical composition having moisture-proof properties, which includes the step of coating the pharmaceutical composition with the above film-forming composition.
  • the present invention provides a method for producing a moisture-proof food composition, which includes the step of coating a food composition with the film-forming composition.
  • the present invention provides a method for coating a pharmaceutical composition, which includes the step of coating a pharmaceutical composition using the above film-forming composition.
  • the present invention provides a method for coating a food composition, which includes the step of coating a food composition using the film-forming composition.
  • the present invention provides a method for moisture-proofing a pharmaceutical composition, which includes the step of coating the pharmaceutical composition with the above film-forming composition.
  • the present invention provides a method for moisture-proofing a food composition, which includes the step of coating the food composition using the film-forming composition.
  • the present invention provides the following inventions [1] to [24].
  • At least one surfactant selected from a nonionic surfactant selected from sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester or a higher alcohol surfactant, and the fatty acid are water-soluble polymers.
  • a water-soluble polymer is used as a base material, and at least one of a nonionic surfactant selected from sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester or a higher alcohol surfactant is added to the base material.
  • a film-like composition in which one surfactant and a fatty acid are dispersed.
  • the sucrose fatty acid ester is sucrose stearate, sucrose caprate, sucrose laurate, sucrose myristate, sucrose palmitate, sucrose oleate, sucrose linoleic acid esters, sucrose ⁇ -linolenic acid ester, sucrose ⁇ -linolenic acid ester, sucrose arachidic acid ester, sucrose arachidonic acid ester, sucrose eicosapentaenoic acid ester, sucrose erucic acid ester, sucrose docosahexaenoic acid ester,
  • the content of the fatty acid in the composition is 0.5 to 10 parts by mass per 1 part by mass of the surfactant in the composition.
  • the polyoxyethylene sorbitan fatty acid ester is polyoxyethylene (20) sorbitan monooleate, polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene monostearate. (20) At least one selected from sorbitan, polyoxyethylene tristearate (20) sorbitan, polyoxyethylene monoisostearate (20) sorbitan, and polyoxyethylene trioleate (20) sorbitan, [1] to The composition according to any one of [6].
  • the water-soluble polymer is at least one selected from hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, hydroxyethylcellulose, carboxymethylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, and polyvinyl alcohol/acrylic acid/methyl methacrylate copolymer.
  • the composition according to any one of [1] to [7] above.
  • the fatty acids are stearic acid, capric acid, lauric acid, myristic acid, palmitic acid, oleic acid, linoleic acid, ⁇ -linolenic acid, ⁇ -linolenic acid, arachidic acid, arachidonic acid, eicosapentaenoic acid, and erucic acid. , docosahexaenoic acid, and behenic acid, the composition according to any one of [1] to [8] above.
  • the higher alcohol surfactant includes stearyl alcohol, cetanol, cetostearyl alcohol, oleyl alcohol, lauryl alcohol, myristyl alcohol, lanolin alcohol, arachidyl alcohol, behenyl alcohol, hexidecanol, isostearyl alcohol, octyldodecanol, and decyl alcohol.
  • the composition according to any one of [1] to [9] above, which is selected from at least one tetradecanol.
  • At least one surfactant selected from a nonionic surfactant selected from sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester or a higher alcohol surfactant, a fatty acid, and a water-soluble polymer A method for producing a film-forming composition, comprising the step of mixing.
  • At least one surfactant selected from a nonionic surfactant selected from sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester or a higher alcohol surfactant and fatty acid are mixed and heated. a step of heating a liquid containing a water-soluble polymer; and a step of adding and mixing the heated liquid to a mixture of the heated surfactant and the fatty acid. Production method.
  • At least one surfactant selected from a nonionic surfactant selected from sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester or a higher alcohol surfactant and fatty acid are mixed and heated. heating a liquid containing a water-soluble polymer, and adding and mixing the heated liquid to the heated mixture of the surfactant and the fatty acid to produce a film-forming composition; A method for producing a pharmaceutical composition having a coating layer, the method comprising forming a coating layer on a pharmaceutical composition using a film-forming composition.
  • a method for producing a pharmaceutical composition having moisture-proof properties comprising the step of coating the pharmaceutical composition with the composition according to any one of [1] to [11] above.
  • a method for producing a moisture-proof food composition comprising the step of coating a food composition with the composition according to any one of [1] to [11] above.
  • a method for coating a pharmaceutical composition comprising the step of coating the pharmaceutical composition using the composition according to any one of [1] to [11] above.
  • a method for coating a food composition comprising the step of coating the food composition using the composition according to any one of [1] to [11] above.
  • a method for moisture-proofing a pharmaceutical composition comprising the step of coating the pharmaceutical composition with the composition according to any one of [1] to [11] above.
  • a method for moisture-proofing a food composition comprising the step of coating the food composition with the composition according to any one of [1] to [11] above.
  • a film-forming composition and a film-like composition with excellent moisture resistance are provided.
  • FIG. 3 is a diagram showing the water vapor permeability of the films of Examples 1 to 8 and Comparative Examples 1 to 4.
  • FIG. 3 is a diagram showing the water vapor permeability of the films of Examples 1, 9 to 12 and Comparative Example 4.
  • FIG. 3 is a diagram showing the results of a hygroscopicity test of uncoated tablets and coated tablets of Examples 1 and 7 and Comparative Examples 5 and 6.
  • FIG. 7 is a diagram showing the results of a hygroscopicity test of coated tablets of Example 12 and Comparative Example 7.
  • x to y (x, y are specific values) means from x to y (ie, inclusive of both extreme values) unless otherwise specified.
  • the film-forming composition of the present embodiment contains at least one surfactant selected from a nonionic surfactant selected from sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester, or a higher alcohol surfactant. and a fatty acid are dispersed in a liquid containing a water-soluble polymer.
  • the film-forming composition can be used as a coating liquid for tablets and the like, and can be made into a film-like composition described below by drying the film-forming composition spread into a film.
  • Sucrose fatty acid ester is a compound in which sucrose and fatty acid are ester bonded, and acts as a nonionic surfactant.
  • the sucrose fatty acid ester can be in the form of monoester, diester, triester, tetraester, pentaester, hexaester, heptaester, or octaester, depending on the number of esterifications of the hydroxyl groups of sucrose.
  • the sucrose fatty acid ester is sucrose represented by the following formula (1), in which at least one of the hydroxy groups [the underlined portion of formula (1)] forms an ester with a fatty acid.
  • the form of the sucrose fatty acid ester is not particularly limited, from monoester to octaester, and it may be in the form of a single ester or may contain multiple esters. Furthermore, there is no particular limitation as to which hydroxy group of sucrose has an ester bond with a fatty acid.
  • the sucrose fatty acid ester preferably contains a monoester, and the monoester ratio of the sucrose fatty acid ester is more preferably 30% or more in molar ratio, more preferably 35% or more, More preferably, it is 40% or more.
  • the number of carbon atoms in the fatty acid contained in the sucrose fatty acid ester is not particularly limited, but is, for example, in the range of 8 to 24 carbon atoms, preferably in the range of 12 to 24 carbon atoms, and more preferably in the range of 14 to 22 carbon atoms. , more preferably in the range of 14 to 20, and even more preferably in the range of 16 to 20.
  • the sucrose fatty acid ester is a diester or higher, the fatty acids bonded to the ester may be the same or different. Further, the fatty acid may be a saturated fatty acid or an unsaturated fatty acid.
  • HLB Hydrophilic Balance
  • sucrose fatty acid ester is not particularly limited, and can take any value higher than 0 and lower than 20.
  • the HLB is defined by the Griffin method, and can be calculated by the following equation (2).
  • HLB 20 ⁇ sum of formula weights of hydrophilic parts/molecular weight (2)
  • the HLB range may be 1 to 19, 2 to 18, 3 to 18, 4 to 18, or 4.5 to 17. It may be 5 to 16, or it may be 7 to 16.
  • sucrose fatty acid esters include sucrose stearate, sucrose caprate, sucrose laurate, sucrose myristate, sucrose palmitate, sucrose oleate, and sucrose linole. acid esters, sucrose ⁇ -linolenic acid ester, sucrose ⁇ -linolenic acid ester, sucrose arachidic acid ester, sucrose arachidonic acid ester, sucrose eicosapentaenoic acid ester, sucrose erucic acid ester, sucrose docosahexaenoic acid ester, and Examples include sucrose behenate. These may be used alone or in combination of two or more.
  • the film-forming composition preferably contains at least sucrose stearate, and more preferably mainly contains sucrose stearate.
  • "mainly contained” refers to 50 mol% or more of the sucrose fatty acid ester in the film-forming composition, preferably 60 mol% or more.
  • sucrose fatty acid ester examples include Ryoto (registered trademark) Sugar Ester S-070, Ryoto (registered trademark) Sugar Ester S-170, Ryoto (registered trademark) Sugar Ester S-270, and Ryoto (registered trademark) manufactured by Mitsubishi Chemical Foods.
  • Polyoxyethylene sorbitan fatty acid ester refers to a compound in which ethylene oxide is condensed with sorbitan fatty acid ester.
  • the number of carbon atoms in the fatty acid constituting the polyoxyethylene sorbitan fatty acid ester is, for example, in the range of 10 to 24, preferably in the range of 10 to 22, more preferably in the range of 12 to 20, and 14 More preferably, it is in the range of ⁇ 20.
  • the average number of added moles of ethylene oxide condensed to polyoxyethylene sorbitan fatty acid ester is, for example, in the range of 6 to 100, preferably in the range of 6 to 70, and in the range of 6 to 50. is more preferable, and a range of 6 to 30 is more preferable.
  • polyoxyethylene sorbitan fatty acid esters examples include polyoxyethylene monooleate (20) sorbitan (polysorbate 80), polyoxyethylene monolaurate (20) sorbitan (polysorbate 20), polyoxyethylene monopalmitate (20) sorbitan (Polysorbate 40), polyoxyethylene monostearate (20) sorbitan (polysorbate 60), polyoxyethylene tristearate (20) sorbitan (polysorbate 65), polyoxyethylene monoisostearate (20) sorbitan, polyoxy trioleate Examples include ethylene (20) sorbitan (polysorbate 85). Among these, polyoxyethylene (20) sorbitan monooleate (polysorbate 80) is preferred. These may be used alone or in combination of two or more.
  • the higher alcohol surfactant refers to a monohydric alcohol having 8 or more carbon atoms.
  • the number of carbon atoms is preferably 10 to 26, more preferably 12 to 24, and even more preferably 14 to 18.
  • higher alcohol surfactants include stearyl alcohol, cetanol, cetostearyl alcohol (a mixture of stearyl alcohol and cetanol), oleyl alcohol, lauryl alcohol, myristyl alcohol, lanolin alcohol, arachidyl alcohol, behenyl alcohol, hexidecanol, and isostearyl alcohol.
  • examples include alcohol, octyldodecanol, decyltetradecanol, and the like. These may be used alone or in combination of two or more.
  • the content of sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester contained in the film-forming composition is not particularly limited, but is, for example, 1 part by mass to 50 parts by mass with respect to 100 parts by mass of the film-forming composition. be able to. Of these, it is preferably in the range of 1 part by mass to 30 parts by mass, more preferably in the range of 1 part to 25 parts by mass, more preferably in the range of 2 parts by mass to 25 parts by mass, It is more preferably in the range of 2 parts by mass to 20 parts by mass, more preferably in the range of 2.5 parts by mass to 20 parts by mass, and even more preferably in the range of 3 parts by mass to 16 parts by mass.
  • the mass of the film-forming composition is the mass of a sufficiently dried film-forming composition that does not contain substantially water.
  • substantially free of water includes not only the case where no water is contained at all, but also the case where a very small amount of water, such as 0.1% by mass or less of the film-forming composition, is contained.
  • the content of the sucrose fatty acid ester, polyoxyethylene sorbitan fatty acid ester, and higher alcohol surfactant contained in the film-forming composition is not particularly limited, but for example, 1 mass per 100 parts by mass of the film-forming composition. parts to 50 parts by mass. Of these, it is preferably in the range of 1 part by mass to 30 parts by mass, more preferably in the range of 1 part to 25 parts by mass, more preferably in the range of 2 parts by mass to 25 parts by mass, It is more preferably in the range of 2 parts by mass to 20 parts by mass, more preferably in the range of 2.5 parts by mass to 20 parts by mass, and even more preferably in the range of 3 parts by mass to 16 parts by mass.
  • the film-forming composition may contain nonionic surfactants other than sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester.
  • nonionic surfactants include, for example, sorbitan fatty acid esters (e.g., sorbitan monooleate, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, sorbitan sesquioleate, sorbitan trioleate, diglycerol sorbitan penta-2-ethylhexylate, diglycerol sorbitan tetra-2-ethylhexylate, etc.), glycerin fatty acids (e.g., glyceryl monoerucate, glyceryl sesquioleate, glyceryl monostearate, ⁇ , ⁇ '-pyrooleate) Glyceryl glutamate, glyceryl monostearate, malic acid, etc.), propylene glycol
  • the content of nonionic surfactants other than sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester in the film-forming composition is not particularly limited, but for example, 20 parts by mass per 100 parts by mass of the film-forming composition.
  • the amount can be as follows, preferably 15 parts by mass or less, more preferably 10 parts by mass or less, more preferably 5 parts by mass or less, and more preferably 3 parts by mass or less.
  • the fatty acid contained in the film-forming composition is not particularly limited, but includes, for example, saturated and unsaturated fatty acids having 4 to 30 carbon atoms.
  • the fatty acid may be linear or branched, but preferably linear.
  • the number of carbon atoms in the fatty acid is, for example, in the range of 10 to 24, preferably in the range of 10 to 22, more preferably in the range of 12 to 20, and more preferably in the range of 14 to 20. preferable.
  • fatty acids examples include butyric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, oleic acid, linoleic acid, ⁇ -linolenic acid, ⁇ -linolenic acid, arachidic acid, and arachidonic acid. , eicosapentaenoic acid, erucic acid, docosahexaenoic acid, behenic acid, elaidic acid, palmitoleic acid, lignoceric acid, and the like.
  • At least one behenic acid is preferably selected from stearic acid, capric acid, lauric acid, myristic acid, palmitic acid, oleic acid, linoleic acid, ⁇ -linolenic acid, ⁇ -linolenic acid, arachidic acid, arachidonic acid,
  • eicosapentaenoic acid, erucic acid, docosahexaenoic acid and behenic acid preferably selected from stearic acid, palmitic acid, palmitoleic acid, oleic acid
  • the content of fatty acids contained in the film-forming composition is not particularly limited, but can be, for example, 5 parts by mass to 50 parts by mass with respect to 100 parts by mass of the film-forming composition. Of these, it is preferably in the range of 7.5 parts by mass to 50 parts by mass, more preferably in the range of 10 parts by mass to 50 parts by mass, and more preferably in the range of 10 parts by mass to 45 parts by mass, It is more preferably in the range of 10 parts by mass to 40 parts by mass, more preferably in the range of 15 parts by mass to 40 parts by mass, and even more preferably in the range of 15 parts by mass to 35 parts by mass.
  • the content of fatty acids contained in the film-forming composition is preferably in the range of 0.5 to 10.0 parts by mass per 1 part by mass of the nonionic surfactant in the film-forming composition.
  • the content of fatty acid contained in the film-forming composition is preferably in the range of 0.5 to 10.0 parts by mass, more preferably in the range of 0.8 to 7.0 parts by mass.
  • the content of fatty acids contained in the film-forming composition is 0.5 to 10.0 parts by mass per 1 part by mass of sucrose fatty acid ester, polyoxyethylene sorbitan fatty acid ester, and higher alcohol surfactant in the film-forming composition. It is preferable that it is in the range of .
  • the content of fatty acid contained in the film-forming composition is preferably in the range of 0.5 to 10.0 parts by mass, more preferably in the range of 0.8 to 7.0 parts by mass.
  • the water-soluble polymer contained in the film-forming composition is not particularly limited, but for example, cellulose-based polymers such as hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, sodium cellulose sulfate, carboxymethylcellulose, and sodium carboxymethylcellulose.
  • carboxymethyl starch methylhydroxypropyl starch, sodium alginate, propylene glycol alginate ester, polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, sodium polyacrylate, polyethyl acrylate, polyacrylamide, xanthan gum, gum arabic, gum tragacanth, galactan, guar gum , carrageenan, pectin, agar, dextran, pullulan, collagen, gelatin, polyvinyl alcohol/acrylic acid/methyl methacrylate copolymer, and the like.
  • the water-soluble polymer may be used alone or in combination of two or more.
  • hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, hydroxyethylcellulose, carboxymethylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, and polyvinyl alcohol/acrylic acid/methyl methacrylate copolymer are preferably selected from at least hydroxypropylcellulose. , hydroxypropyl methylcellulose, methylcellulose, hydroxyethylcellulose, carboxymethylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, and polyvinyl alcohol/acrylic acid/methyl methacrylate copolymer, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose.
  • polyvinyl alcohol hydroxyethyl cellulose, carboxymethyl cellulose, polyvinyl alcohol, and polyvinyl alcohol/acrylic acid/methyl methacrylate copolymer.
  • the polyvinyl alcohol and the polyvinyl alcohol/acrylic acid/methyl methacrylate copolymer are preferably partially saponified products.
  • Examples of the polyvinyl alcohol/acrylic acid/methyl methacrylate copolymer include POVACOAT (registered trademark) manufactured by Nissin Kasei Co., Ltd., and the like.
  • the content of the water-soluble polymer contained in the film-forming composition is not particularly limited, but can be, for example, 20 parts by mass to 90 parts by mass with respect to 100 parts by mass of the film-forming composition.
  • the content of the water-soluble polymer is preferably in the range of 30 parts by mass to 90 parts by mass, more preferably in the range of 35 parts by mass to 85 parts by mass, and in the range of 35 parts by mass to 80 parts by mass. It is more preferable that
  • the content of the water-soluble polymer contained in the film-forming composition can be 2 to 20 parts by mass per 1 part by mass of the nonionic surfactant in the film-forming composition. Of these, it is preferably in the range of 3 to 20 parts by mass, and more preferably in the range of 4 to 20 parts by mass.
  • the content of the water-soluble polymer contained in the film-forming composition is 2 to 1 part by mass of the sucrose fatty acid ester, polyoxyethylene sorbitan fatty acid ester, and higher alcohol surfactant in the film-forming composition. It can be 20 parts by mass. Of these, it is preferably in the range of 3 to 20 parts by mass, and more preferably in the range of 4 to 20 parts by mass.
  • the water-soluble polymer is dissolved or dispersed in the liquid (aqueous medium). That is, the liquid containing a water-soluble polymer is an aqueous solution or dispersion of the water-soluble polymer.
  • the liquid include, but are not limited to, water, ethanol, propanol, and mixtures thereof, with water being preferred.
  • the state in which the water-soluble polymer is dispersed in the liquid includes, for example, the state in which hydroxypropyl cellulose heated to 50° C. or higher is dispersed in the liquid. Hydroxypropylcellulose is soluble in water at room temperature, but at temperatures above 50°C, the molecules aggregate and disperse instead of dissolving. In such cases, the water-soluble polymer is dispersed in the liquid.
  • a method for dispersing the surfactant and the fatty acid in a liquid containing a water-soluble polymer for example, a mixer or a stirrer may be used. Examples of mixers and agitators include homogenizers, dissolvers, homomixers, and planetary mixers.
  • An example of a preferable form of the film-forming composition is a combination of sucrose stearate as the sucrose fatty acid ester, hydroxypropyl methylcellulose as the water-soluble polymer, and stearic acid as the fatty acid, and the film-forming composition contains
  • the content of the fatty acid contained in the film-forming composition is in the range of 0.5 to 10.0 parts by mass per 1 part by mass of the nonionic surfactant in the film-forming composition.
  • the film-forming composition is a combination of stearyl alcohol as a surfactant, polyvinyl alcohol as a water-soluble polymer, and stearic acid as a fatty acid, and the fatty acid contained in the film-forming composition.
  • the amount is in the range of 0.5 to 10.0 parts by mass per 1 part by mass of the surfactant in the film-forming composition.
  • the film-forming composition is a combination of stearyl alcohol as a surfactant, polyvinyl alcohol/acrylic acid/methyl methacrylate copolymer as a water-soluble polymer, and stearic acid as a fatty acid;
  • the content of the fatty acid contained in the film-forming composition is in the range of 0.5 to 10.0 parts by mass per 1 part by mass of the surfactant in the film-forming composition.
  • the film-forming composition may contain additives as necessary.
  • additives include excipients, stabilizers, sweeteners, colorants, antioxidants, lubricants, and the like.
  • excipients examples include sugars, sugar alcohols, phosphates, gluten, chitosan, pectin, albumin, casein, and glycine.
  • sugars include lactose hydrate, white sugar, trehalose, sucrose, maltose, and isomers thereof.
  • sugar alcohols include D-sorbitol and D-mannitol.
  • phosphates include sodium phosphate, calcium phosphate, potassium phosphate, and the like. The excipients may be used alone or in combination of two or more.
  • the stabilizer examples include calcium chloride, calcium chloride hydrate, calcium chloride dihydrate, dibutylhydroxytoluene, alanine, sodium chloride, magnesium oxide, bentonite, talc, magnesium aluminate metasilicate, and the like.
  • One type of stabilizer may be used, or two or more types may be used in combination. Among these, preferably bentonite is included.
  • sweeteners examples include acesulfame potassium, sucralose, aspartame, and saccharin sodium.
  • One type of sweetener may be used, or two or more types may be used in combination.
  • coloring agent examples include iron sesquioxide, yellow iron sesquioxide, zinc oxide, titanium oxide, iron oxide, and the like.
  • the coloring agent may be used alone or in combination of two or more.
  • fragrances include strawberry micron, peppermint micron, peach micron, lychee micron, and pineapple micron.
  • One type of fragrance may be used, or two or more types may be used in combination.
  • antioxidants include ascorbic acid, citric acid, maleic acid, malonic acid, succinic acid, fumaric acid, tocopherols, benzotriazole, dibutylhydroxytoluene, butylhydroxyanisole, pyrosulfite, gallic acid ester, and ethylenediaminetetrachloride. Examples include acetic acid.
  • the antioxidant may be used alone or in combination of two or more.
  • lubricants examples include talc, magnesium stearate, calcium stearate, stearic acid, light silicic anhydride, and the like.
  • the lubricant may be used alone or in combination of two or more.
  • the content of the additive contained in the film-forming composition is, for example, 50 parts by mass or less, 30 parts by mass or less, 25 parts by mass or less, 20 parts by mass or less, 15 parts by mass or less, based on 100 parts by mass of the film-forming composition. parts by weight or less, 12.5 parts by weight or less, 10 parts by weight or less, 7.5 parts by weight or less, 5 parts by weight or less, 4 parts by weight or less, 3 parts by weight or less, or 1 part by weight or less.
  • One embodiment of the present invention is a film composition obtained from the film-forming composition described above.
  • the film-like composition can be obtained by drying the film-forming composition.
  • the water-soluble polymer is present as a base material, and at least one of a nonionic surfactant selected from sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester or a higher alcoholic surfactant is selected.
  • a surfactant and a fatty acid are dispersed in the substrate.
  • At least one surfactant selected from a nonionic surfactant selected from sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester or a higher alcohol surfactant, the fatty acid, and the water-soluble polymer are as described above. It is.
  • the content of sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester contained in the film composition is not particularly limited, but may be, for example, 1 part by mass to 50 parts by mass with respect to 100 parts by mass of the film composition. can. Of these, it is preferably in the range of 1 part by mass to 30 parts by mass, more preferably in the range of 1 part to 25 parts by mass, more preferably in the range of 2 parts by mass to 25 parts by mass, It is more preferably in the range of 2 parts by mass to 20 parts by mass, more preferably in the range of 2.5 parts by mass to 20 parts by mass, and even more preferably in the range of 3 parts by mass to 16 parts by mass.
  • the content of the sucrose fatty acid ester, polyoxyethylene sorbitan fatty acid ester, and higher alcohol surfactant contained in the film composition is not particularly limited, but is, for example, 1 part by mass to 100 parts by mass of the film composition. It can be 50 parts by mass. Of these, it is preferably in the range of 1 part by mass to 30 parts by mass, more preferably in the range of 1 part to 25 parts by mass, more preferably in the range of 2 parts by mass to 25 parts by mass, It is more preferably in the range of 2 parts by mass to 20 parts by mass, more preferably in the range of 2.5 parts by mass to 20 parts by mass, and even more preferably in the range of 3 parts by mass to 16 parts by mass.
  • the content of fatty acids contained in the film composition is not particularly limited, but can be, for example, 5 parts by mass to 50 parts by mass based on 100 parts by mass of the film composition. Of these, it is preferably in the range of 10 parts by mass to 50 parts by mass, more preferably in the range of 10 parts by mass to 45 parts by mass, and more preferably in the range of 10 parts by mass to 40 parts by mass, It is more preferably in the range of 15 parts by mass to 40 parts by mass, and even more preferably in the range of 15 parts by mass to 35 parts by mass.
  • the content of the water-soluble polymer contained in the film composition is not particularly limited, but can be, for example, 20 parts by mass to 90 parts by mass with respect to 100 parts by mass of the film composition. Of these, the range is preferably from 30 parts by mass to 90 parts by mass, and more preferably from 35 parts by mass to 90 parts by mass.
  • the content of fatty acids contained in the film composition is preferably 0.5 to 10.0 parts by mass, and preferably 0.8 to 7.0 parts by mass, per 1 part by mass of the nonionic surfactant in the film composition. is more preferable.
  • the film composition may be formed on the surface of a tablet or capsule, or may form a film or sheet by itself. By making it into a film or sheet, it can be used as, for example, a wafer, a wrap, a moisture-proof film, etc.
  • One embodiment of the present invention is a pharmaceutical composition coated with the above film-forming composition.
  • the form (dosage form) of the pharmaceutical composition is not particularly limited, and examples include tablets, pills, fine granules, capsules, and granules. Capsules may be hard capsules or soft capsules. Moreover, the capsule may be coated with the capsule itself, or the fine particles encapsulated in the capsule may be coated.
  • the additives contained in the film-forming composition described above are preferably selected from pharmaceutically acceptable additives.
  • the pharmaceutical composition coated with the film-forming composition is not particularly limited, and can contain various active ingredients.
  • the active ingredient refers to a pharmaceutical ingredient or nutritional supplement ingredient used as a medicine, supplement, or the like.
  • Pharmaceutical ingredients include, for example, acarbose, nonsteroidal antirheumatic drugs, cardiac glycosides, acetylsalicylic acid, viral inhibitors, aclarubicin, acyclovir, cisplatin, actinomycin, ⁇ - and ⁇ -sympathomimetic drugs, allopurinol, alosetron, Alprostadil, prostaglandins, amantadine, ambroxol, amlodipine, methotrexate, S-aminosalicylic acid, amitriptyline, amlodipine, amoxicillin, anastrozole, atenolol, atorvastatin, azathioprine, balsalazide, beclomethasone, betahistine,
  • These pharmaceutical ingredients also include pharmaceutically acceptable salts of pharmaceutical ingredients or solvates thereof.
  • pharmaceutically acceptable salt refers to a salt formed from a pharmaceutical ingredient compound and an organic or inorganic acid or base that is acceptable for administration to mammals including humans.
  • pharmaceutically acceptable salts include phosphates, hydrochlorides, sulfates, acetates, ammonium salts, amine salts, nitrates, and carbonates.
  • a solvate of a pharmaceutically acceptable salt refers to a solid molecule formed from a pharmaceutical ingredient compound or a pharmaceutically acceptable salt thereof and a solvent that is acceptable for administration to mammals including humans. say. Examples of such solvents include water, ethanol, and the like.
  • Examples of nutritional supplement ingredients include vitamin B 1 , vitamin B 2 , vitamin B 6 , vitamin B 12 , vitamin C, vitamin D, vitamin E, caffeine, iron oxide, zinc dioxide, citric acid, medium chain fatty acid triglyceride, Docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), hyaluronic acid, chondroitin sulfate, collagen hydrolyzate, edible oils (sesame oil, soybean oil, olive oil, safflower oil, etc.), sesamin, ⁇ -aminobutyric acid, rare sugars ( (D-psicose, D-allose, etc.), crude drug extract, Chinese herbal extract, tea extract, shellfish extract, yeast extract, lactic acid bacteria extract, animal cell extract, yeast culture liquid, lactic acid bacteria culture liquid, animal cell culture Examples include liquid. These active ingredients may be used alone or in combination. Extracts and culture solutions such as crude drug extracts may be concentrated.
  • the pharmaceutical composition may be for oral administration or for parenteral administration (for example, transdermal administration, intravascular administration, intramuscular administration, etc.). Moreover, it may be for humans, animals, or plants. When used for plants, the active ingredients may include known pesticides and fertilizers.
  • One embodiment of the present invention is a food composition coated with the above film-forming composition.
  • the form of the food composition is not particularly limited, and can take the various forms described above.
  • the food composition may be used as a health food, a functional food, a food for specified health use, a food with nutritional function claims, a food with functional claims, a quasi-drug, or a nutritional supplement.
  • the food composition may contain the above-mentioned nutritional supplement ingredients.
  • the film-forming composition may be present so as to completely cover the pharmaceutical composition or food composition, or it may not be completely covered, but it is preferably present so as to completely cover the pharmaceutical composition or food composition. .
  • the thickness of the coating layer of the pharmaceutical composition or food composition made of the film-forming composition is not particularly limited, and can be adjusted as appropriate depending on the shape and use of the pharmaceutical composition.
  • the coating layer herein refers to a film-forming composition formed by coating a pharmaceutical composition or a food composition with a film-forming composition, or a film-like composition obtained by drying a film-forming composition. Refers to layers. Although the thickness of the coating layer may or may not be uniform, it is preferable that the surface of the pharmaceutical composition or food composition after the coating layer is formed is smooth with few undulations.
  • the pharmaceutical composition or food composition coated with the film-forming composition of the present invention may have one or more layers.
  • a state in which there are a plurality of coating layers of the film-forming composition of the present invention means, for example, that the coating layer of the film-forming composition of the present invention is further coated with another layer of a coating agent, and there is another coating layer of the film-forming composition of the present invention. Examples include the case where a layer of the composition is formed.
  • Coating agents used in the layer of other coating agents include, for example, ammonioalkyl methacrylate copolymers (RLPO, RSPO), aminoalkyl methacrylate copolymers E, aminoalkyl methacrylate copolymers RS, carnauba wax, beeswax, gypsum, shellac, bentonite, oxidized Examples include titanium, talc, triethyl citrate, and the like.
  • One type of coating agent may be used, or two or more types may be used in combination.
  • the film composition of the present invention has excellent moisture resistance, it is possible to suppress moisture from being contained in a pharmaceutical composition or a food composition coated with the film composition. Therefore, for example, active ingredients that are highly reactive with water can be prevented from reacting with water and deteriorating, and the shelf life of pharmaceutical compositions and food compositions can be improved.
  • compositions and food compositions may be packaged using PTP packaging, bottle filling, aluminum packaging, etc., as necessary.
  • materials for PTP packaging include resins such as polyvinyl chloride, polypropylene, polyvinylidene chloride, polychlorotrifluoroethylene, polyethylene, polystyrene, or polycarbonate, and metals such as aluminum. These materials may be used alone or in combination. Examples of combinations include laminating polyvinyl chloride and polyvinylidene chloride, laminating polyvinyl chloride and polychlorotrifluoroethylene, and the like.
  • the tablets can be packaged by placing the tablets in the molded pockets of a resin sheet molded from the above-mentioned resin by a known method and covering the tablets with aluminum foil.
  • the PTP packaging may be further wrapped with an aluminum pillow.
  • This aluminum pillow may further contain a desiccant and an oxygen scavenger.
  • the desiccant include calcium chloride, calcium oxide, magnesium oxide, silica gel, and zeolite.
  • oxygen scavenger include iron-based oxygen scavengers such as iron powder, organic oxygen scavengers such as ascorbic acid, isoascorbic acid, hydroquinone, or catechol, and the like. These desiccants and oxygen scavengers may be used alone or in combination of multiple types, or may be used in combination of desiccant and oxygen scavenger. Examples of products that combine a desiccant and an oxygen scavenger include "Pharma Keep (registered trademark)" by Mitsubishi Gas Chemical Co., Ltd.
  • compositions and food compositions may be filled into glass bottles or plastic bottles as necessary, or may be packaged into single-dose packages in aluminum packaging.
  • Examples of the material for the plastic bottle include the above-mentioned PTP packaging resin.
  • the aluminum package may be further wrapped with an aluminum pillow. This aluminum pillow may further contain the desiccant and oxygen scavenger described above.
  • the present invention includes at least one surfactant selected from a nonionic surfactant selected from sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester or a higher alcohol surfactant, and a water-soluble polymer.
  • a method for producing a film-forming composition which includes a step of mixing a liquid and a fatty acid.
  • the mixing method includes at least one surfactant selected from a nonionic surfactant selected from sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester or a higher alcohol surfactant, a fatty acid, and a water-soluble highly water-soluble surfactant.
  • the above-mentioned stirrer or mixer can be used.
  • the solvent for dissolving the water-soluble polymer include water, ethanol, propanol, and a mixture thereof, with water being preferred.
  • the fatty acid is mixed with at least one surfactant selected from a nonionic surfactant selected from sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester or a higher alcoholic surfactant.
  • a film-forming composition comprising the steps of: heating a liquid containing a water-soluble polymer; and adding and mixing a heated mixture of a surfactant and a fatty acid to the heated liquid.
  • a nonionic surfactant selected from sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester (optionally, a nonionic surfactant other than sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester may be further included); or At least one surfactant selected from higher alcohol surfactants and a fatty acid are mixed.
  • the shape of the sucrose fatty acid ester used is not particularly limited, and may be in the form of granules, powder, or fine powder.
  • the mixture is heated during or after mixing the surfactant and the fatty acid. Although the heating temperature is not particularly limited, it is preferable that the mixture of the surfactant and the fatty acid be heated to a temperature equal to or higher than the melting point of the fatty acid.
  • the above-mentioned additives may be added when mixing the surfactant and fatty acid.
  • the heating device used in the present invention is not particularly limited, and any known heating device, constant temperature bath, or the like can be used.
  • a solution containing the water-soluble polymer is prepared by dissolving the water-soluble polymer in a solvent.
  • the above-mentioned stirrer or mixer can be used to dissolve the water-soluble polymer.
  • the solvent include water, ethanol, propanol, and a mixture thereof, with water being preferred.
  • the above-mentioned additives may be added when mixing the water-soluble polymer and the solvent.
  • the liquid containing the water-soluble polymer is heated during or after mixing the water-soluble polymer and the solvent. Although the heating temperature is not particularly limited, it is preferable to heat to a temperature equal to or higher than the melting point of the fatty acid used in the mixture of the surfactant and fatty acid.
  • a film-forming composition can be obtained by adding a mixture of the surfactant and fatty acid to a liquid containing a water-soluble polymer and dispersing the surfactant and fatty acid.
  • a stirring device or the like known in the technical field can be used.
  • the above-mentioned stirrer or mixer may be used.
  • the obtained film-forming composition can be used as a coating agent for the above-mentioned pharmaceutical compositions and food compositions. Alternatively, it can be dried to form a film composition.
  • the present invention uses a water-soluble polymer as a base material, and contains at least one nonionic surfactant selected from sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester or a higher alcohol surfactant.
  • a method for producing a film-like composition in which one surfactant and a fatty acid are dispersed can be obtained by drying the film-forming composition.
  • the drying method is not particularly limited, and any known drying method can be used. Examples include natural drying, drying using a vacuum dryer, drying using spray drying, and drying using freeze drying.
  • a film-forming composition is coated on the surface of a tablet, capsule, etc., and when it dries, a film-like composition is formed on the surface of the tablet, capsule, etc.
  • a film-forming composition is poured into a mold or the like and dried and solidified, a film-like composition for film or sheet tablets can be obtained.
  • Such a film composition can be used, for example, as a wafer, a wrap, a moisture-proof film, and the like.
  • a method for forming a film composition on the surface of a tablet or capsule can be, for example, by coating the above film-forming composition on the surface of a tablet or capsule and drying the film-forming composition.
  • a known coating method can be used.
  • a pan coating method, a rolling coating method, a fluidized bed coating method, etc. can be used.
  • Coating can also be achieved by dipping a tablet or the like in the film-forming composition.
  • the film-forming composition may be applied to aluminum foil, polypropylene, polyethylene terephthalate (PET) or polyimide film, nonwoven fabric, etc. to form the film.
  • the film may be formed by using an extrusion molding machine.
  • the coating method is not particularly limited, but for example, the film-forming composition can be applied by attaching it to a pan coating device and spraying the film-forming composition thereon. Alternatively, it can be carried out using a device such as a spin coater, gravure coater, applicator, multi-coater, die coater, bar coater, roll coater, blade coater, or knife coater.
  • the thickness of the film is not particularly limited and can be appropriately selected depending on the application. For example, it can be 10 nm to 5000 ⁇ m.
  • One embodiment of the present invention has a coating layer, which includes the steps of producing a film-forming composition and forming a coating layer on a pharmaceutical composition or a food composition using the produced film-forming composition.
  • a method for producing a pharmaceutical composition or a food composition is as described above.
  • the coating layer can be formed by coating the surface of a tablet, capsule, etc. with a film-forming composition.
  • the coating method is as described above.
  • the formed coating layer is a layer of a film-like composition.
  • One embodiment of the present invention is a method for producing a pharmaceutical composition or food composition having moisture-proof properties, which includes the step of coating a pharmaceutical composition or food composition with the film-forming composition of the present invention.
  • the method for producing the film-forming composition in this method is as described above.
  • the step of coating a pharmaceutical composition or a food composition can be performed, for example, by coating the surface of a tablet, capsule, or the like with a film-forming composition.
  • the coating method is as described above.
  • moisture-proofing properties can be imparted to the pharmaceutical composition or food composition coated with the film-forming composition.
  • the formed coating layer is a layer of a film-like composition.
  • One embodiment of the present invention is a method for coating a pharmaceutical composition or a food composition or a moisture-proofing method, which includes the step of coating a pharmaceutical composition or a food composition using the film-forming composition of the present invention.
  • Moisture-proofing of the pharmaceutical composition or food composition coated with the film-forming composition can be achieved by coating the pharmaceutical composition or food composition with the film-forming composition dispersed in the film-forming composition to form a coating layer. can improve sex.
  • the details of the film-forming composition and its manufacturing method in this method are as described above.
  • Experimental Example 1 Evaluation of moisture permeability of film A film was produced using the film-forming composition of the present invention, and its permeability was evaluated. The film was manufactured as follows. The thickness of each film produced was in the range of 50 to 100 ⁇ m (this thickness was measured at five arbitrary locations on each circularly cut film using a micrometer).
  • Example 2 (Production of coating liquid and film of Example 2)
  • the amounts of water, HPC, stearic acid, and surfactant 1 used are 650 g of water, 32.5 g of HPC, 12.5 g of stearic acid, and 5.0 g of surfactant 1 (mixing ratio [mass] is HPC: stearic acid: surfactant
  • Example 3 (Production of coating liquid and film of Example 3)
  • the amounts of water, HPC, stearic acid, and surfactant 1 used are 650 g of water, 32.5 g of HPC, 15.0 g of stearic acid, and 2.5 g of surfactant 1 (mixing ratio [mass] is HPC: stearic acid: surfactant
  • Example 4 (Production of coating liquid and film of Example 4)
  • the coating solution of Example 4 was prepared in the same manner as in Example 1 except that Ryoto (registered trademark) Sugar Ester S-770 (surfactant 2: HLB 7) manufactured by Mitsubishi Chemical Corporation was used instead of surfactant 1. And the film of Example 4 was obtained.
  • Ryoto registered trademark
  • Sugar Ester S-770 surfactant 2: HLB 7
  • Example 5 (Production of coating liquid and film of Example 5)
  • the coating solution of Example 5 was prepared in the same manner as in Example 1 except that Ryoto (registered trademark) Sugar Ester S-970 (Surfactant 3: HLB 9) manufactured by Mitsubishi Chemical Corporation was used instead of Surfactant 1. And the film of Example 5 was obtained.
  • Surfactant 3 is used instead of surfactant 1, and the amounts of water, HPC, stearic acid, and surfactant 3 used are 650 g of water, 32.5 g of HPC, 12.5 g of stearic acid, and 5.0 g of surfactant 3 (
  • Example 7 (Production of coating liquid and film of Example 7) A coating liquid of Example 7 and a film of Example 7 were obtained in the same manner as in Example 1 except that Polysorbate 80 (Surfactant 4: HLB 15) was used instead of Surfactant 1.
  • Polysorbate 80 Surfactant 4: HLB 15
  • Example 10 (Production of coating liquid and film of Example 10) The coating solution and method of Example 10 were carried out in the same manner as in Example 9 except that polyvinyl alcohol/acrylic acid/methyl methacrylate copolymer (POVACOAT manufactured by Nissin Kasei Co., Ltd.) was used instead of polyvinyl alcohol as the water-soluble polymer. A film of Example 10 was obtained.
  • polyvinyl alcohol/acrylic acid/methyl methacrylate copolymer POVACOAT manufactured by Nissin Kasei Co., Ltd.
  • Example 11 (Production of coating liquid and film of Example 11) A coating liquid of Example 11 and a film of Example 11 were obtained in the same manner as in Example 10, except that stearyl alcohol (Koliwax SA manufactured by BASF: Surfactant 7) was used instead of Surfactant 1.
  • stearyl alcohol Koliwax SA manufactured by BASF: Surfactant 7
  • Example 12 was obtained by stirring with a stirrer. A coating liquid was obtained. This coating liquid was sprayed toward the coating pan in the same manner as in Example 1, and the coating film was sufficiently dried to obtain a film of Example 12.
  • a coating liquid of Comparative Example 1 and a film of Comparative Example 1 were obtained in the same manner as in Example 1 except that Poloxamer 188 manufactured by BASF (Surfactant 5: HLB 16) was used instead of Surfactant 1. .
  • a coating liquid of Comparative Example 6 was obtained by adding and dissolving 45 g of hydroxypropyl cellulose in 900 g of water.
  • the moisture permeability of the films was measured using each of the films of Examples 1 to 12 and Comparative Examples 1 to 4. Moisture permeability was measured as follows using a moisture permeable cup manufactured by Elcometer.
  • the mass of the test device before the test was measured and used as the mass at the start of the experiment. 6.
  • the test device from 4. was placed in a thermostat at 75% relative humidity and 25°C for 24 hours. 7.
  • the mass of the test device in 6. was measured.
  • the mass increase over 24 hours was calculated from the measured values in 5. and 7.
  • Water vapor permeability (W ⁇ A)/(B ⁇ C) (3) During the ceremony, W is mass increased in 24 hours (g) A is film thickness (mm) B is the transmission area (cm 2 ) C refers to atmospheric pressure (atm). Note that in this experiment, the atmospheric pressure was 1 atm.
  • the measurement results for each film of Examples 1 to 12 and Comparative Examples 1 to 4 are shown in Tables 1 to 3 and FIGS. 1A and B.
  • the measurement results were the average value of three measurements for each film.
  • FIG. 1A shows the results of the films of Examples 1 to 8 and Comparative Examples 1 to 4
  • FIG. 1B shows the results of Examples 1, 9 to 12, and Comparative Example 4.
  • 1A and B it was found that the water vapor permeability of the films of Examples 1 to 12 was lower than that of Comparative Examples 1 to 4.
  • a nonionic surfactant selected from sucrose fatty acid ester and polyoxyethylene sorbitan fatty acid ester or a higher alcohol surfactant reduces the water vapor permeability of the film.
  • Examples 1 to 6 and 9 to 12 had lower water vapor permeability.
  • Numerical values other than water vapor permeability represent the mass ratio of each component during film production. Water during production is not included in the composition.
  • Numerical values other than water vapor permeability represent the mass ratio of each component during film production. Water during production is not included in the composition.
  • Numerical values other than water vapor permeability represent the mass ratio of each component during film production. Water during production is not included in the composition.
  • Experimental example 2 Evaluation of moisture permeability of tablets 1 Tablets coated with the film-forming composition of the present invention were manufactured and their moisture permeability was evaluated. The tablets used in the experiment were manufactured as follows.
  • a granulation liquid was obtained by dispersing 108 g of crospovidone and 240 g of corn starch in 1080 g of water. 792.1 g of D-mannitol, 24 g of ethyl cellulose, 24 g of crystalline cellulose, and 12 g of light anhydrous silicic acid were placed in a fluidized bed granulation dryer, and the above granulation liquid was added thereto for granulation to produce rapidly disintegrating granules.
  • Coated tablets were manufactured using the coating liquids of Examples 1 and 7 and Comparative Examples 5 and 6 as follows.
  • the numerical value of each component is mass ratio (%) Water during production is not included in the composition.
  • the measurement results for each tablet are shown in Figure 2.
  • the uncoated tablet in FIG. 2 refers to uncoated tablet A.
  • Wa represents the tablet mass (g) before the start of the test
  • Wb represents the tablet mass (g) at the time of measurement.
  • a portion of the obtained mixed powder was taken and compressed using a rotary tablet machine and a punch with a tablet diameter of 9 mm so that the mass of each tablet was 260 mg to obtain tablets (uncoated tablets B). Ta.
  • a coating liquid of Comparative Example 7 was prepared by mixing 85 kg of absolute ethanol and 6.882 kg of water, adding 2.856 kg of hypromellose, 5.712 kg of ethyl cellulose, 0.816 kg of glycerin fatty acid ester, and 0.816 kg of talc and stirring.
  • FIG. 3 shows the measurement results for each tablet.
  • the moisture absorption amount in FIG. 3 is the increase in mass of 10 tablets. From FIG. 3, it can be seen that the tablet of Comparative Example 7 increases in moisture absorption with each passing day, whereas the tablet of Example 12 shows almost no increase in mass even after 14 days have passed. From this, it can be understood that the tablet coated with the film-forming composition of the present invention has excellent moisture resistance.
  • Coated tablets can be manufactured, for example, as follows.
  • moisture-proof film coating 11 800 g of sustained-release film-coated tablets were placed in a coating device and coated so that the coating amount per tablet was 27.63 mg to obtain moisture-proof film-coated tablets.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
PCT/JP2023/018619 2022-05-18 2023-05-18 膜形成用組成物、膜状組成物及びその利用 Ceased WO2023224097A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US18/865,316 US20250302753A1 (en) 2022-05-18 2023-05-18 Membrane-forming composition, membrane-like composition, and use of same
JP2024521982A JPWO2023224097A1 (cg-RX-API-DMAC7.html) 2022-05-18 2023-05-18
EP23807698.8A EP4527411A4 (en) 2022-05-18 2023-05-18 MEMBRANE FORMING COMPOSITION, MEMBRANE TYPE COMPOSITION AND THEIR USES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022-081879 2022-05-18
JP2022081879 2022-05-18

Publications (1)

Publication Number Publication Date
WO2023224097A1 true WO2023224097A1 (ja) 2023-11-23

Family

ID=88835299

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2023/018619 Ceased WO2023224097A1 (ja) 2022-05-18 2023-05-18 膜形成用組成物、膜状組成物及びその利用

Country Status (4)

Country Link
US (1) US20250302753A1 (cg-RX-API-DMAC7.html)
EP (1) EP4527411A4 (cg-RX-API-DMAC7.html)
JP (1) JPWO2023224097A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023224097A1 (cg-RX-API-DMAC7.html)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08198778A (ja) * 1995-01-23 1996-08-06 Shin Etsu Chem Co Ltd 徐放性製剤コーティング用水分散液
WO2010074223A1 (ja) * 2008-12-25 2010-07-01 東レ株式会社 固形製剤用のコーティング剤及びこれを用いた固形製剤
WO2011105539A1 (ja) * 2010-02-26 2011-09-01 東レ株式会社 被覆固形製剤
JP2012520832A (ja) * 2009-03-18 2012-09-10 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング ポリマー混合物と賦形剤とを含むコーティングを使用するエタノールの影響に対する耐性を有する制御放出性医薬組成物
JP2013519686A (ja) * 2010-02-12 2013-05-30 センシエント カラーズ エルエルシー 腸溶性コーティング組成物ならびにその製造法および使用法
JP2013525397A (ja) * 2010-04-26 2013-06-20 ディーエスエム アイピー アセッツ ビー.ブイ. 新規なコーティング系
JP2014534959A (ja) * 2011-10-14 2014-12-25 ディーエスエム アイピー アセッツ ビー.ブイ. 新規コーティングシステム
JP2017522894A (ja) * 2014-07-31 2017-08-17 アモーフィカル リミテッド. カプセル化された非晶質炭酸カルシウム組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003090723A1 (en) * 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
US20170128379A1 (en) * 2014-06-30 2017-05-11 Rubicon Research Private Limited Modified release pharmaceutical preparations

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08198778A (ja) * 1995-01-23 1996-08-06 Shin Etsu Chem Co Ltd 徐放性製剤コーティング用水分散液
WO2010074223A1 (ja) * 2008-12-25 2010-07-01 東レ株式会社 固形製剤用のコーティング剤及びこれを用いた固形製剤
JP2012520832A (ja) * 2009-03-18 2012-09-10 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング ポリマー混合物と賦形剤とを含むコーティングを使用するエタノールの影響に対する耐性を有する制御放出性医薬組成物
JP2013519686A (ja) * 2010-02-12 2013-05-30 センシエント カラーズ エルエルシー 腸溶性コーティング組成物ならびにその製造法および使用法
WO2011105539A1 (ja) * 2010-02-26 2011-09-01 東レ株式会社 被覆固形製剤
JP2013525397A (ja) * 2010-04-26 2013-06-20 ディーエスエム アイピー アセッツ ビー.ブイ. 新規なコーティング系
JP2014534959A (ja) * 2011-10-14 2014-12-25 ディーエスエム アイピー アセッツ ビー.ブイ. 新規コーティングシステム
JP2017522894A (ja) * 2014-07-31 2017-08-17 アモーフィカル リミテッド. カプセル化された非晶質炭酸カルシウム組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADEL PENHASI ET AL., JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, vol. 40, 2017, pages 105 - 115
See also references of EP4527411A4

Also Published As

Publication number Publication date
EP4527411A4 (en) 2026-04-08
JPWO2023224097A1 (cg-RX-API-DMAC7.html) 2023-11-23
EP4527411A1 (en) 2025-03-26
US20250302753A1 (en) 2025-10-02

Similar Documents

Publication Publication Date Title
US6962717B1 (en) Pharmaceutical compositions
ES2298236T3 (es) Forma medicamentosa de particulas multiples, que contiene por lo menos dos formas de granulos, revestidas de manera diferente.
ES2248291T3 (es) Agente de recubrimiento y aglutinante para formulaciones de medicamento con estabilidad al almcenamiento mejorada.
EP3705118B1 (en) Oral solid dosage form composition having improved disintegration and preparation method therefor
US7175857B2 (en) Granulate or powder for producing coating or binding agents for medicaments
US20080026040A1 (en) Active agent-releasing dosage forms
CN101987082B (zh) 固体制剂及其制备方法
CN101453993A (zh) 含有机溶胶涂层的受控释放递送物件
EP2983650B1 (en) Oral pharmaceutical composition comprising taste-masked n-acetylcysteine
CN102365083A (zh) 采用包含聚合物混合物和赋形剂的包衣的具有耐乙醇影响的控释药物组合物
ES2784134T3 (es) Comprimidos con cubierta y producción de los mismos
JPWO2013129644A1 (ja) 速崩壊性錠剤
CN101820866B (zh) 用于固体剂型的机械保护层
CN101903017B (zh) 具有增强的脉冲活性物质释放的包衣的药物或营养制剂
US20250302753A1 (en) Membrane-forming composition, membrane-like composition, and use of same
US8962064B2 (en) Production of pulverulent coating compositions for stable protective coatings for pharmaceutical dosage forms
CN104159576B (zh) 在中性环境中具有良好抗性的药物保护性涂层的制备
RU2376013C2 (ru) Пероральный препарат и способ его получения
JP7584413B2 (ja) 時限式溶出マスキング粒子およびそれを含有する経口医薬組成物
US20130236505A1 (en) Production Of Pharmaceutical Protective Coatings With Good Resistance In A Neutral Environment
JP2010260803A (ja) キサンタンガム被覆水溶性糖類及び圧縮成形製剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23807698

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 18865316

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2024521982

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2023807698

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023807698

Country of ref document: EP

Effective date: 20241218

WWP Wipo information: published in national office

Ref document number: 18865316

Country of ref document: US